PuSH - Publikationsserver des Helmholtz Zentrums München

Demel, U.M.* ; Boger, M.* ; Yousefian, S.* ; Grunert, C.* ; Zhang, L.* ; Hotz, P.W.* ; Gottschlich, A.* ; Köse, H.* ; Isaakidis, K.* ; Vonficht, D.* ; Grünschläger, F.* ; Rohleder, E.* ; Wagner, K.* ; Dönig, J.* ; Igl, V.* ; Brzezicha, B.* ; Baumgartner, F.* ; Habringer, S.* ; Löber, J.* ; Chapuy, B.* ; Weidinger, C.* ; Kobold, S. ; Busse, A.B.* ; Müller, S.* ; Wirth, M.* ; Schick, M.* ; Keller, U.*

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.

J. Clin. Invest. 132:e152383 (2022)
Postprint Forschungsdaten DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell-mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell-mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Antigen Presentation ; Immunology ; Immunotherapy ; Oncology ; Ubiquitin-proteosome System
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Zeitschrift Journal of Clinical Investigation
Quellenangaben Band: 132, Heft: 9, Seiten: , Artikelnummer: e152383 Supplement: ,
Verlag American Society of Clinical Investigation
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen Deutsche Forschungsgemeinschaft
European Research Council
Wilhelm-Sander foundation
TCR2 Inc.
H2020 Program of the European Union
Arcus Bioscience
Charité – Universitätsmedizin Berlin
Deutsche Krebshilfe
Stiftung Charité
Berlin Institute of Health